# Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter

> **NCT01229254** · PHASE2 · COMPLETED · sponsor: **Portola Pharmaceuticals** · enrollment: 189 (actual)

## Conditions studied

- Atrial Fibrillation
- Atrial Flutter

## Interventions

- **DRUG:** Amiodarone
- **DRUG:** Betrixaban 60 mg
- **DRUG:** Betrixaban 90 mg
- **DRUG:** Betrixaban 30 mg

## Key facts

- **NCT ID:** NCT01229254
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2010-12
- **Final completion:** 2011-04
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2023-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01229254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01229254, "Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01229254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*